Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acute myelogenous leukemia (AML) is the most common
leukemia
in adults with clonal proliferation of myeloid stem cells. Two or more cooperating mechanisms, namely block in differentiation, enhanced proliferation and resistance to programmed cell death, underlie this neoplastic transformation. Nonrandom, complete and partial deletions of chromosome 5 are common anomalies in AML. Using positional cloning strategies, we characterized an evolutionarily conserved candidate myeloid leukemia suppressor gene encoding sequence-specific
single-stranded DNA binding protein 2
(
SSBP2
) from chromosome 5q13.3, a locus that is frequently deleted in AML. Recent studies in Drosophila and Xenopus demonstrate a pivotal role for SSBPs in embryonic differentiation. In mammals,
SSBP2
is one of three highly related and ubiquitously expressed genes. Here, we identify frequent loss of
SSBP2
protein expression in human AML cell lines using highly specific antibodies. Furthermore, inducible expression of
SSBP2
in the AML cell line U937 leads to loss of clonogenicity, G1 arrest and partial differentiation. Remarkably, inducible expression of
SSBP2
is accompanied by downregulation of C-MYC expression. Our findings are consistent with human
SSBP2
being a novel regulator of hematopoietic growth and differentiation, whose loss confers a block in differentiation advantage to myeloid leukemic cells.
...
PMID:SSBP2, a candidate tumor suppressor gene, induces growth arrest and differentiation of myeloid leukemia cells. 1578 45